Local Treatment of Hand-Foot Syndrome with Uridine/Thymidine:In Vitro Appraisal on a Human Keratinocyte Cell Line HaCaT

Simple item page
dc.contributor.authorHartinger, Jancs
dc.contributor.authorVeselý, Pavelcs
dc.contributor.authorMatoušková, Evacs
dc.contributor.authorArgalacsová, Soňacs
dc.contributor.authorPetruželka, Lubošcs
dc.contributor.authorNetíková, Irenacs
dc.coverage.issue7cs
dc.coverage.volume2012cs
dc.date.accessioned2020-08-04T11:04:18Z
dc.date.available2020-08-04T11:04:18Z
dc.date.issued2012-07-31cs
dc.description.abstract5-fluorouracil (5-FU) is one of the most commonly used antineoplastic drugs in the anticancer therapy. The hand-foot (HF) syndrome (palmar-plantar erythrodysesthesia) is an adverse effect frequently related to long-term i.v. administration of 5-FU or its orally applicable prodrug capecitabine. Its severity can even lead to interruption of the otherwise effective anticancer therapy. Tentative practice in some clinics has shown that topical application of 10% uridine ointment is beneficial for calming down the HF syndrome. This study is focused on verifying the alleged protective activity of uridine in the in vitro model of cultured human keratinocyte cell line HaCaT. We also tested the protective effects of thymidine alone or uridine-thymidine combination. The cellular viability time progression was measured in order to evaluate the effect of protective agents by three different types of cytopathogenicity tests - NTCA test (non-destructive test of cellular activity), modified MTT test and RTCA (real-time cell analyser, Roche). All three methods proved the ability of uridine and uridine-thymidine combination to protect keratinocytes against 5-FU damage in vitro. While thymidine alone did not show any remarkable effect, the thymidine-uridine combination demonstrated enhanced protective activity compared to uridine alone. Our findings provided the supporting rationale for using uridine or uridine-thymidine ointments in the HF syndrome local therapy.en
dc.description.abstract5-fluorouracil je užíván běžně pro léčbu různých nádorů. Jako obtěžující negativní vliv této léčby se vykytuje výskyt zánětlivého podráždění dlaní a plosky nohou. Lokálně aplikovaná mast s uridinem tyto příznaky odstraňuje. Provedená in vitro studie prokázala racionální důvod tohoto přístupu tím, že zjistila in vitro ochranný účinek uridinu a thymidinu na buňky HACAT vystavené působení 5-fluorouracilu.cs
dc.formattextcs
dc.format.extent1-6cs
dc.format.mimetypeapplication/pdfcs
dc.identifier.citationThe Scientific World Journal. 2012, vol. 2012, issue 7, p. 1-6.en
dc.identifier.doi10.1100/2012/421325cs
dc.identifier.issn1537-744Xcs
dc.identifier.other99043cs
dc.identifier.urihttp://hdl.handle.net/11012/84150
dc.language.isoencs
dc.publisherHindawics
dc.relation.ispartofThe Scientific World Journalcs
dc.relation.urihttps://www.hindawi.com/journals/tswj/2012/421325/cs
dc.rightsCreative Commons Attribution 3.0 Unportedcs
dc.rights.accessopenAccesscs
dc.rights.sherpahttp://www.sherpa.ac.uk/romeo/issn/1537-744X/cs
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/cs
dc.subject5-fluorouracil Hand-Foot syndrom uridine thymidineen
dc.subject5-fluouracil Hand-Foot syndrom uridin thymidin
dc.titleLocal Treatment of Hand-Foot Syndrome with Uridine/Thymidine:In Vitro Appraisal on a Human Keratinocyte Cell Line HaCaTen
dc.title.alternativeLokální léčba Hand-Foot syndromu uridinem/thymidinem: In vitro ocenění na linii lidských keratinocytů HACATcs
dc.type.driverarticleen
dc.type.statusPeer-revieweden
dc.type.versionpublishedVersionen
sync.item.dbidVAV-99043en
sync.item.dbtypeVAVen
sync.item.insts2020.09.02 06:59:25en
sync.item.modts2020.09.01 08:17:11en
thesis.grantorVysoké učení technické v Brně. Středoevropský technologický institut VUT. Experimentální biofotonikacs
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
421325.pdf
Size:
2.36 MB
Format:
Adobe Portable Document Format
Description:
421325.pdf
Download
Collections
Experimentální biofotonika